Consequently, targeting the activation of SIRT1 and deacetylation of p53 may be a viable therapeutic approach to mitigate premature renal failure and delay the progression of CKD following AKI (Fan et al., 2013; Fu et al., 2022). This evidence concerns the gene TP53 and chronic kidney disease.